TORONTO, July 10, 2014 /CNW/ - Lorus Therapeutics Inc.
(TSX: LOR) today announced that the Company will release its fourth
quarter and year end 2014 financial results on Tuesday, July 15, 2014 after the close of the
market. The company intends to host a conference call on the
same day at 5:00 p.m. EDT to discuss
the financial results.
Participants can access the conference call by dialing
1-888-231-8191 (North American toll free number) or 647-427-7450
(local). The conference call will be available via a live
webcast at
http://www.newswire.ca/en/webcast/detail/1384185/1535487, and will
also available through a link on the Investor Relations section of
Lorus' website at http://lorusthera.com/news-events/events.php.
Please log onto the webcast at least 10 minutes prior to the start
of the call to ensure time for any software downloads that may be
required. An archived version of the webcast will be
available on the company's website for 30 days. An audio
replay of the webcast will be available approximately two hours
after the conclusion of the call for 30 days by dialing
1-855-859-2056, using the passcode 72210243.
The press release, the financial statements and the management's
discussion and analysis for the quarter and year ended May 31, 2014 will be available on SEDAR at
www.sedar.com.
About Lorus
Lorus is a clinical-stage biotechnology company with a commitment
to discovering and developing targeted therapies addressing unmet
medical needs in oncology. We aim to develop therapeutics focused
on novel cellular targets on the leading edge of cancer research
coupled to companion diagnostics to identify the optimal patient
population for our products. Our pipeline of cancer drug
candidates includes small molecule products and immunotherapies
providing additive or synergistic efficacy without leading to
overlapping toxicities with existing anti-cancer regimens,
facilitating the adoption of doublet or possibly triplet therapies.
Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol
LOR.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Canadian and US securities laws. Such statements
include, but are not limited to, statements relating to the
Company's plans, objectives, expectations and intentions and other
statements including words such as "continue", "expect", "intend",
"will", "should", "would", "may", and other similar expressions.
Such statements reflect our current views with respect to future
events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such risks and uncertainties could
include, among others: our ability to continue to operate as a
going concern; our ability to obtain the capital required for
research and operations; the inherent risks in early stage drug
development including demonstrating efficacy; development time/cost
and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with
potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed
from time-to-time in our ongoing quarterly filings, annual
information forms, annual reports and annual filings with Canadian
securities regulators and the United
States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in our filings with Canadian securities regulators and the
United States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward looking
statements are made as of the date of this press release and we do
not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. Such
statements may not prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty
therein.
SOURCE Lorus Therapeutics Inc.